A serological survey on neutralizing antibody titer of SARS convalescent sera
Identifieur interne : 000414 ( Istex/Corpus ); précédent : 000413; suivant : 000415A serological survey on neutralizing antibody titer of SARS convalescent sera
Auteurs : Jian-San Zhang ; Jiang-Ting Chen ; Yu-Xuan Liu ; Zhen-Shan Zhang ; Hong Gao ; Yan Liu ; Xu Wang ; Ye Ning ; Yu-Fen Liu ; Qiang Gao ; Jian-Guo Xu ; Chuan Qin ; Xiao-Ping Dong ; Wei-Dong YinSource :
- Journal of Medical Virology [ 0146-6615 ] ; 2005-10.
English descriptors
- Teeft :
- Antibody, Assay, Beijing, Convalescent, Convalescent sera, Coronavirus, Elisa, Hebei province, Immunosorbent assay, Inner mongolia, Neutralization, Neutralization assay, Neutralizing, Neutralizing antibody titer, Normal distribution, Passive transfer, Positive sera, Respiratory syndrome, Sars, Sars cases, Sars convalescent sera, Sars patients, Sars vaccine, Serum samples, Syndrome, Titer, Vaccine, Vero cells, Western blot.
Abstract
A seroepidemiologic study was conducted in North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region, Hebei Province, and Beijing 35–180 days after the onset of symptoms. The anti‐SARS antibodies were detected by enzyme‐linked immunosorbent assay (ELISA), neutralization assay, and Western blot. Eighty‐seven serum samples were confirmed to be positive for SARS antibodies. The neutralizing antibody titer of the 87 positive sera was analyzed quantitatively by neutralization assay. The geometric mean titer (GMT) of the 87 convalescent sera was 1:61. The Kolmogorov–Smirnov test showed that the neutralizing antibody titers conform to normal distribution, which suggests that the average anti‐SARS antibody level in this study was representative of the convalescent antibody level of the SARS population. This result could be useful for the development and quality control of SARS vaccines. J. Med. Virol. 77:147–150, 2005. © 2005 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jmv.20431
Links to Exploration step
ISTEX:F066BD559402A5F38564C58EA794B07017CF14D3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A serological survey on neutralizing antibody titer of SARS convalescent sera</title><author><name sortKey="Zhang, Jian An" sort="Zhang, Jian An" uniqKey="Zhang J" first="Jian-San" last="Zhang">Jian-San Zhang</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Chen, Jiang Ing" sort="Chen, Jiang Ing" uniqKey="Chen J" first="Jiang-Ting" last="Chen">Jiang-Ting Chen</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Liu, Yu Uan" sort="Liu, Yu Uan" uniqKey="Liu Y" first="Yu-Xuan" last="Liu">Yu-Xuan Liu</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Zhang, Zhen Han" sort="Zhang, Zhen Han" uniqKey="Zhang Z" first="Zhen-Shan" last="Zhang">Zhen-Shan Zhang</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Gao, Hong" sort="Gao, Hong" uniqKey="Gao H" first="Hong" last="Gao">Hong Gao</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Liu, Yan" sort="Liu, Yan" uniqKey="Liu Y" first="Yan" last="Liu">Yan Liu</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Wang, Xu" sort="Wang, Xu" uniqKey="Wang X" first="Xu" last="Wang">Xu Wang</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Ning, Ye" sort="Ning, Ye" uniqKey="Ning Y" first="Ye" last="Ning">Ye Ning</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Liu, Yu En" sort="Liu, Yu En" uniqKey="Liu Y" first="Yu-Fen" last="Liu">Yu-Fen Liu</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Gao, Qiang" sort="Gao, Qiang" uniqKey="Gao Q" first="Qiang" last="Gao">Qiang Gao</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Xu, Jian Uo" sort="Xu, Jian Uo" uniqKey="Xu J" first="Jian-Guo" last="Xu">Jian-Guo Xu</name><affiliation><mods:affiliation>Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Qin, Chuan" sort="Qin, Chuan" uniqKey="Qin C" first="Chuan" last="Qin">Chuan Qin</name><affiliation><mods:affiliation>The Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Dong, Xiao Ing" sort="Dong, Xiao Ing" uniqKey="Dong X" first="Xiao-Ping" last="Dong">Xiao-Ping Dong</name><affiliation><mods:affiliation>Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Yin, Wei Ong" sort="Yin, Wei Ong" uniqKey="Yin W" first="Wei-Dong" last="Yin">Wei-Dong Yin</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: yinwd@sinovac.com</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Sinovac Biotech Co. Ltd., No. 39 Shangdi Xi Rd., Haidian District, Beijing 100085, China.===</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F066BD559402A5F38564C58EA794B07017CF14D3</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/jmv.20431</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-CTTG3L81-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000414</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000414</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">A serological survey on neutralizing antibody titer of SARS convalescent sera</title><author><name sortKey="Zhang, Jian An" sort="Zhang, Jian An" uniqKey="Zhang J" first="Jian-San" last="Zhang">Jian-San Zhang</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Chen, Jiang Ing" sort="Chen, Jiang Ing" uniqKey="Chen J" first="Jiang-Ting" last="Chen">Jiang-Ting Chen</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Liu, Yu Uan" sort="Liu, Yu Uan" uniqKey="Liu Y" first="Yu-Xuan" last="Liu">Yu-Xuan Liu</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Zhang, Zhen Han" sort="Zhang, Zhen Han" uniqKey="Zhang Z" first="Zhen-Shan" last="Zhang">Zhen-Shan Zhang</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Gao, Hong" sort="Gao, Hong" uniqKey="Gao H" first="Hong" last="Gao">Hong Gao</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Liu, Yan" sort="Liu, Yan" uniqKey="Liu Y" first="Yan" last="Liu">Yan Liu</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Wang, Xu" sort="Wang, Xu" uniqKey="Wang X" first="Xu" last="Wang">Xu Wang</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Ning, Ye" sort="Ning, Ye" uniqKey="Ning Y" first="Ye" last="Ning">Ye Ning</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Liu, Yu En" sort="Liu, Yu En" uniqKey="Liu Y" first="Yu-Fen" last="Liu">Yu-Fen Liu</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Gao, Qiang" sort="Gao, Qiang" uniqKey="Gao Q" first="Qiang" last="Gao">Qiang Gao</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Xu, Jian Uo" sort="Xu, Jian Uo" uniqKey="Xu J" first="Jian-Guo" last="Xu">Jian-Guo Xu</name><affiliation><mods:affiliation>Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Qin, Chuan" sort="Qin, Chuan" uniqKey="Qin C" first="Chuan" last="Qin">Chuan Qin</name><affiliation><mods:affiliation>The Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Dong, Xiao Ing" sort="Dong, Xiao Ing" uniqKey="Dong X" first="Xiao-Ping" last="Dong">Xiao-Ping Dong</name><affiliation><mods:affiliation>Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Yin, Wei Ong" sort="Yin, Wei Ong" uniqKey="Yin W" first="Wei-Dong" last="Yin">Wei-Dong Yin</name><affiliation><mods:affiliation>Sinovac Biotech Co. Ltd., Beijing, China</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: yinwd@sinovac.com</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Sinovac Biotech Co. Ltd., No. 39 Shangdi Xi Rd., Haidian District, Beijing 100085, China.===</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><biblScope unit="vol">77</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="147">147</biblScope><biblScope unit="page" to="150">150</biblScope><biblScope unit="page-count">4</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-10">2005-10</date></imprint><idno type="ISSN">0146-6615</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antibody</term><term>Assay</term><term>Beijing</term><term>Convalescent</term><term>Convalescent sera</term><term>Coronavirus</term><term>Elisa</term><term>Hebei province</term><term>Immunosorbent assay</term><term>Inner mongolia</term><term>Neutralization</term><term>Neutralization assay</term><term>Neutralizing</term><term>Neutralizing antibody titer</term><term>Normal distribution</term><term>Passive transfer</term><term>Positive sera</term><term>Respiratory syndrome</term><term>Sars</term><term>Sars cases</term><term>Sars convalescent sera</term><term>Sars patients</term><term>Sars vaccine</term><term>Serum samples</term><term>Syndrome</term><term>Titer</term><term>Vaccine</term><term>Vero cells</term><term>Western blot</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A seroepidemiologic study was conducted in North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region, Hebei Province, and Beijing 35–180 days after the onset of symptoms. The anti‐SARS antibodies were detected by enzyme‐linked immunosorbent assay (ELISA), neutralization assay, and Western blot. Eighty‐seven serum samples were confirmed to be positive for SARS antibodies. The neutralizing antibody titer of the 87 positive sera was analyzed quantitatively by neutralization assay. The geometric mean titer (GMT) of the 87 convalescent sera was 1:61. The Kolmogorov–Smirnov test showed that the neutralizing antibody titers conform to normal distribution, which suggests that the average anti‐SARS antibody level in this study was representative of the convalescent antibody level of the SARS population. This result could be useful for the development and quality control of SARS vaccines. J. Med. Virol. 77:147–150, 2005. © 2005 Wiley‐Liss, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>sars</json:string><json:string>neutralization assay</json:string><json:string>neutralizing</json:string><json:string>elisa</json:string><json:string>convalescent</json:string><json:string>assay</json:string><json:string>western blot</json:string><json:string>neutralizing antibody titer</json:string><json:string>coronavirus</json:string><json:string>neutralization</json:string><json:string>beijing</json:string><json:string>respiratory syndrome</json:string><json:string>vaccine</json:string><json:string>convalescent sera</json:string><json:string>serum samples</json:string><json:string>vero cells</json:string><json:string>sars convalescent sera</json:string><json:string>titer</json:string><json:string>positive sera</json:string><json:string>sars vaccine</json:string><json:string>sars patients</json:string><json:string>immunosorbent assay</json:string><json:string>sars cases</json:string><json:string>normal distribution</json:string><json:string>passive transfer</json:string><json:string>inner mongolia</json:string><json:string>hebei province</json:string><json:string>syndrome</json:string><json:string>antibody</json:string></teeft></keywords><author><json:item><name>Jian‐San Zhang</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string></affiliations></json:item><json:item><name>Jiang‐Ting Chen</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string></affiliations></json:item><json:item><name>Yu‐Xuan Liu</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string></affiliations></json:item><json:item><name>Zhen‐Shan Zhang</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string></affiliations></json:item><json:item><name>Hong Gao</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string></affiliations></json:item><json:item><name>Yan Liu</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string></affiliations></json:item><json:item><name>Xu Wang</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string></affiliations></json:item><json:item><name>Ye Ning</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string></affiliations></json:item><json:item><name>Yu‐Fen Liu</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string></affiliations></json:item><json:item><name>Qiang Gao</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string></affiliations></json:item><json:item><name>Jian‐Guo Xu</name><affiliations><json:string>Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</json:string></affiliations></json:item><json:item><name>Chuan Qin</name><affiliations><json:string>The Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China</json:string></affiliations></json:item><json:item><name>Xiao‐Ping Dong</name><affiliations><json:string>Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</json:string></affiliations></json:item><json:item><name>Wei‐Dong Yin</name><affiliations><json:string>Sinovac Biotech Co. Ltd., Beijing, China</json:string><json:string>E-mail: yinwd@sinovac.com</json:string><json:string>Correspondence address: Sinovac Biotech Co. Ltd., No. 39 Shangdi Xi Rd., Haidian District, Beijing 100085, China.===</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>geometric mean titer</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>immunity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neutralization assay</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>SARS</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>SARS‐CoV</value></json:item></subject><articleId><json:string>JMV20431</json:string></articleId><arkIstex>ark:/67375/WNG-CTTG3L81-5</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>A seroepidemiologic study was conducted in North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region, Hebei Province, and Beijing 35–180 days after the onset of symptoms. The anti‐SARS antibodies were detected by enzyme‐linked immunosorbent assay (ELISA), neutralization assay, and Western blot. Eighty‐seven serum samples were confirmed to be positive for SARS antibodies. The neutralizing antibody titer of the 87 positive sera was analyzed quantitatively by neutralization assay. The geometric mean titer (GMT) of the 87 convalescent sera was 1:61. The Kolmogorov–Smirnov test showed that the neutralizing antibody titers conform to normal distribution, which suggests that the average anti‐SARS antibody level in this study was representative of the convalescent antibody level of the SARS population. This result could be useful for the development and quality control of SARS vaccines. J. Med. Virol. 77:147–150, 2005. © 2005 Wiley‐Liss, Inc.</abstract><qualityIndicators><score>6.792</score><pdfWordCount>2824</pdfWordCount><pdfCharCount>17630</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>4</pdfPageCount><pdfPageSize>594 x 792 pts</pdfPageSize><pdfWordsPerPage>706</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>164</abstractWordCount><abstractCharCount>1135</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>A serological survey on neutralizing antibody titer of SARS convalescent sera</title><pmid><json:string>16121363</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Journal of Medical Virology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1096-9071</json:string></doi><issn><json:string>0146-6615</json:string></issn><eissn><json:string>1096-9071</json:string></eissn><publisherId><json:string>JMV</json:string></publisherId><volume>77</volume><issue>2</issue><pages><first>147</first><last>150</last><total>4</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Research Article</value></json:item></subject></host><namedEntities><unitex><date><json:string>2005</json:string><json:string>2003</json:string></date><geogName></geogName><orgName><json:string>GBI Biotech Co.</json:string><json:string>China Institute for Communicable Disease Control and Prevention</json:string><json:string>Inner Mongolia Autonomous Region, Hebei Province, and Beijing</json:string><json:string>Taiwan, Singapore, and the Chinese</json:string><json:string>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences</json:string><json:string>Inner Mongolia Autonomous Region</json:string><json:string>Inner Mongolia Autonomous Region, Zhangjiakou CDC of Hebei Province, and Beijing CDC</json:string><json:string>Ministry of Health</json:string><json:string>Chinese Center for Disease Control and Prevention</json:string><json:string>Research on Inactivated SARS Vaccine</json:string><json:string>Wiley-Liss, Inc</json:string><json:string>LISS, INC.</json:string><json:string>Sinovac Biotech Co.</json:string><json:string>American Type Culture Collection</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Ye Ning</json:string><json:string>Time Intervals</json:string><json:string>Zhen-Shan Zhang</json:string><json:string>I. Number</json:string><json:string>China</json:string><json:string>Xu Wang</json:string><json:string>Yan Liu</json:string><json:string>J. Med</json:string><json:string>Hong Gao</json:string><json:string>CoV</json:string><json:string>Geometric</json:string><json:string>Vienna</json:string></persName><placeName><json:string>Beijing</json:string><json:string>China</json:string><json:string>Puri</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Gao et al., 2003</json:string><json:string>Wu et al., 2004</json:string><json:string>Zhang et al.</json:string><json:string>Huang et al., 2004</json:string><json:string>Subbarao et al., 2004</json:string><json:string>Marshall and Enserink, 2004</json:string><json:string>Drosten et al., 2003</json:string><json:string>[2003]</json:string><json:string>Bisht et al., 2004</json:string><json:string>Yang et al.</json:string><json:string>Liu et al., 2004</json:string><json:string>Zhang et al., 2005</json:string><json:string>Kuiken et al., 2003</json:string><json:string>Reed and Muench, 1938</json:string><json:string>Shi et al., 2003</json:string><json:string>Li et al., 2003</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-CTTG3L81-5</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - virology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Virology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/jmv.20431</json:string></doi><id>F066BD559402A5F38564C58EA794B07017CF14D3</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-CTTG3L81-5/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-CTTG3L81-5/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-CTTG3L81-5/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">A serological survey on neutralizing antibody titer of SARS convalescent sera</title><title level="a" type="short" xml:lang="en">SARS Neutralizing Antibody Titer</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><licence>Copyright © 2005 Wiley‐Liss, Inc.</licence></availability><date type="published" when="2005-10"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">A serological survey on neutralizing antibody titer of SARS convalescent sera</title><title level="a" type="short" xml:lang="en">SARS Neutralizing Antibody Titer</title><author xml:id="author-0000"><persName><forename type="first">Jian‐San</forename><surname>Zhang</surname></persName><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Jiang‐Ting</forename><surname>Chen</surname></persName><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Yu‐Xuan</forename><surname>Liu</surname></persName><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Zhen‐Shan</forename><surname>Zhang</surname></persName><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Hong</forename><surname>Gao</surname></persName><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Yan</forename><surname>Liu</surname></persName><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Xu</forename><surname>Wang</surname></persName><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">Ye</forename><surname>Ning</surname></persName><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">Yu‐Fen</forename><surname>Liu</surname></persName><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0009"><persName><forename type="first">Qiang</forename><surname>Gao</surname></persName><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0010"><persName><forename type="first">Jian‐Guo</forename><surname>Xu</surname></persName><affiliation><orgName type="institution">Institute for Communicable Disease Control and Prevention</orgName><orgName type="institution">Chinese Center for Disease Control and Prevention</orgName><address><addrLine>Beijing</addrLine><addrLine>China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0011"><persName><forename type="first">Chuan</forename><surname>Qin</surname></persName><affiliation><orgName type="institution">The Institute of Laboratory Animal Science</orgName><orgName type="institution">Chinese Academy of Medical Sciences and Peking Union Medical College</orgName><address><addrLine>Beijing</addrLine><addrLine>China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0012"><persName><forename type="first">Xiao‐Ping</forename><surname>Dong</surname></persName><affiliation><orgName type="institution">Institute for Viral Disease Control and Prevention</orgName><orgName type="institution">Chinese Center for Disease Control and Prevention</orgName><address><addrLine>Beijing</addrLine><addrLine>China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0013" role="corresp"><persName><forename type="first">Wei‐Dong</forename><surname>Yin</surname></persName><email>yinwd@sinovac.com</email><affiliation><address><addrLine>Sinovac Biotech Co. Ltd.</addrLine><addrLine>Beijing, China</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><idno type="istex">F066BD559402A5F38564C58EA794B07017CF14D3</idno><idno type="ark">ark:/67375/WNG-CTTG3L81-5</idno><idno type="DOI">10.1002/jmv.20431</idno><idno type="unit">JMV20431</idno><idno type="toTypesetVersion">file:JMV.JMV20431.pdf</idno></analytic><monogr><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="pISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><idno type="book-DOI">10.1002/(ISSN)1096-9071</idno><idno type="book-part-DOI">10.1002/jmv.v77:2</idno><idno type="product">JMV</idno><imprint><biblScope unit="vol">77</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="147">147</biblScope><biblScope unit="page" to="150">150</biblScope><biblScope unit="page-count">4</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-10"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>A seroepidemiologic study was conducted in North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region, Hebei Province, and Beijing 35–180 days after the onset of symptoms. The anti‐SARS antibodies were detected by enzyme‐linked immunosorbent assay (ELISA), neutralization assay, and Western blot. Eighty‐seven serum samples were confirmed to be positive for SARS antibodies. The neutralizing antibody titer of the 87 positive sera was analyzed quantitatively by neutralization assay. The geometric mean titer (GMT) of the 87 convalescent sera was 1:61. The Kolmogorov–Smirnov test showed that the neutralizing antibody titers conform to normal distribution, which suggests that the average anti‐SARS antibody level in this study was representative of the convalescent antibody level of the SARS population. This result could be useful for the development and quality control of SARS vaccines. J. Med. Virol. 77:147–150, 2005. © 2005 Wiley‐Liss, Inc.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="kwd1">geometric mean titer</term><term xml:id="kwd2">immunity</term><term xml:id="kwd3">neutralization assay</term><term xml:id="kwd4">SARS</term><term xml:id="kwd5">SARS‐CoV</term></keywords><keywords rend="articleCategory"><term>Research Article</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-CTTG3L81-5/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1096-9071</doi><issn type="print">0146-6615</issn><issn type="electronic">1096-9071</issn><idGroup><id type="product" value="JMV"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="JOURNAL OF MEDICAL VIROLOGY">Journal of Medical Virology</title><title type="short">J. Med. Virol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/jmv.v77:2</doi><numberingGroup><numbering type="journalVolume" number="77">77</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2005-10">October 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="1" status="forIssue"><doi origin="wiley" registered="yes">10.1002/jmv.20431</doi><idGroup><id type="unit" value="JMV20431"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title></titleGroup><copyright ownership="publisher">Copyright © 2005 Wiley‐Liss, Inc.</copyright><eventGroup><event type="manuscriptAccepted" date="2005-05-18"></event><event type="firstOnline" date="2005-08-24"></event><event type="publishedOnlineFinalForm" date="2005-08-24"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-15"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-20"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-30"></event></eventGroup><numberingGroup><numbering type="pageFirst">147</numbering><numbering type="pageLast">150</numbering></numberingGroup><correspondenceTo>Sinovac Biotech Co. Ltd., No. 39 Shangdi Xi Rd., Haidian District, Beijing 100085, China.===</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JMV.JMV20431.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="797"></count></countGroup><titleGroup><title type="main" xml:lang="en">A serological survey on neutralizing antibody titer of SARS convalescent sera</title><title type="short" xml:lang="en">SARS Neutralizing Antibody Titer</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jian‐San</givenNames><familyName>Zhang</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jiang‐Ting</givenNames><familyName>Chen</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Yu‐Xuan</givenNames><familyName>Liu</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Zhen‐Shan</givenNames><familyName>Zhang</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Hong</givenNames><familyName>Gao</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Yan</givenNames><familyName>Liu</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Xu</givenNames><familyName>Wang</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Ye</givenNames><familyName>Ning</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Yu‐Fen</givenNames><familyName>Liu</familyName></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Qiang</givenNames><familyName>Gao</familyName></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Jian‐Guo</givenNames><familyName>Xu</familyName></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Chuan</givenNames><familyName>Qin</familyName></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Xiao‐Ping</givenNames><familyName>Dong</familyName></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Wei‐Dong</givenNames><familyName>Yin</familyName></personName><contactDetails><email>yinwd@sinovac.com</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CN" type="organization"><unparsedAffiliation>Sinovac Biotech Co. Ltd., Beijing, China</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CN" type="organization"><unparsedAffiliation>Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="CN" type="organization"><unparsedAffiliation>The Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="CN" type="organization"><unparsedAffiliation>Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">geometric mean titer</keyword><keyword xml:id="kwd2">immunity</keyword><keyword xml:id="kwd3">neutralization assay</keyword><keyword xml:id="kwd4">SARS</keyword><keyword xml:id="kwd5">SARS‐CoV</keyword></keywordGroup><fundingInfo><fundingAgency>Research on Inactivated SARS Vaccine</fundingAgency><fundingNumber>2003AA208201</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>A seroepidemiologic study was conducted in North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region, Hebei Province, and Beijing 35–180 days after the onset of symptoms. The anti‐SARS antibodies were detected by enzyme‐linked immunosorbent assay (ELISA), neutralization assay, and Western blot. Eighty‐seven serum samples were confirmed to be positive for SARS antibodies. The neutralizing antibody titer of the 87 positive sera was analyzed quantitatively by neutralization assay. The geometric mean titer (GMT) of the 87 convalescent sera was 1:61. The Kolmogorov–Smirnov test showed that the neutralizing antibody titers conform to normal distribution, which suggests that the average anti‐SARS antibody level in this study was representative of the convalescent antibody level of the SARS population. This result could be useful for the development and quality control of SARS vaccines. J. Med. Virol. 77:147–150, 2005. © 2005 Wiley‐Liss, Inc.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>A serological survey on neutralizing antibody titer of SARS convalescent sera</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>SARS Neutralizing Antibody Titer</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>A serological survey on neutralizing antibody titer of SARS convalescent sera</title></titleInfo><name type="personal"><namePart type="given">Jian‐San</namePart><namePart type="family">Zhang</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jiang‐Ting</namePart><namePart type="family">Chen</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yu‐Xuan</namePart><namePart type="family">Liu</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Zhen‐Shan</namePart><namePart type="family">Zhang</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hong</namePart><namePart type="family">Gao</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yan</namePart><namePart type="family">Liu</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Xu</namePart><namePart type="family">Wang</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ye</namePart><namePart type="family">Ning</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yu‐Fen</namePart><namePart type="family">Liu</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Qiang</namePart><namePart type="family">Gao</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jian‐Guo</namePart><namePart type="family">Xu</namePart><affiliation>Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chuan</namePart><namePart type="family">Qin</namePart><affiliation>The Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Xiao‐Ping</namePart><namePart type="family">Dong</namePart><affiliation>Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wei‐Dong</namePart><namePart type="family">Yin</namePart><affiliation>Sinovac Biotech Co. Ltd., Beijing, China</affiliation><affiliation>E-mail: yinwd@sinovac.com</affiliation><affiliation>Correspondence address: Sinovac Biotech Co. Ltd., No. 39 Shangdi Xi Rd., Haidian District, Beijing 100085, China.===</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-10</dateIssued><dateValid encoding="w3cdtf">2005-05-18</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">17</extent><extent unit="words">797</extent></physicalDescription><abstract lang="en">A seroepidemiologic study was conducted in North China in 2003 to determine the neutralizing antibody titer of severe acute respiratory syndrome (SARS) convalescent sera. A total of 99 SARS convalescent serum samples were collected from patients from the Inner Mongolia Autonomous Region, Hebei Province, and Beijing 35–180 days after the onset of symptoms. The anti‐SARS antibodies were detected by enzyme‐linked immunosorbent assay (ELISA), neutralization assay, and Western blot. Eighty‐seven serum samples were confirmed to be positive for SARS antibodies. The neutralizing antibody titer of the 87 positive sera was analyzed quantitatively by neutralization assay. The geometric mean titer (GMT) of the 87 convalescent sera was 1:61. The Kolmogorov–Smirnov test showed that the neutralizing antibody titers conform to normal distribution, which suggests that the average anti‐SARS antibody level in this study was representative of the convalescent antibody level of the SARS population. This result could be useful for the development and quality control of SARS vaccines. J. Med. Virol. 77:147–150, 2005. © 2005 Wiley‐Liss, Inc.</abstract><note type="funding">Research on Inactivated SARS Vaccine - No. 2003AA208201; </note><subject lang="en"><genre>keywords</genre><topic>geometric mean titer</topic><topic>immunity</topic><topic>neutralization assay</topic><topic>SARS</topic><topic>SARS‐CoV</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Medical Virology</title></titleInfo><titleInfo type="abbreviated"><title>J. Med. Virol.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0146-6615</identifier><identifier type="eISSN">1096-9071</identifier><identifier type="DOI">10.1002/(ISSN)1096-9071</identifier><identifier type="PublisherID">JMV</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>147</start><end>150</end><total>4</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Bisht</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Roberts</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Vogel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Bukreyev</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PL</namePart><namePart type="family">Collins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BR</namePart><namePart type="family">Murphy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Subbarao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Moss</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. 2004. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101: 6641–6646.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>6641</start><end>6646</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci USA</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>6641</start><end>6646</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Gunther</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Preiser</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">van der Werf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HR</namePart><namePart type="family">Brodt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Becker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Rabenau</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Panning</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Kolesnikova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Fouchier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Berger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Burguiere</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Cinatl</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Eickmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Escriou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Grywna</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Kramme</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Manuguerra</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Muller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Rickerts</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Sturmer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Vieth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HD</namePart><namePart type="family">Klenk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AD</namePart><namePart type="family">Osterhaus</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Schmitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HW</namePart><namePart type="family">Doerr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967–1976.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1967</start><end>1976</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1967</start><end>1976</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Effects of a SARS‐associated coronavirus vaccine in monkeys</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Gao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tamin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Soloff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">D'Aiuto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Nwanegbo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PD</namePart><namePart type="family">Robbins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WJ</namePart><namePart type="family">Bellini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Barratt‐Boyes</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt‐Boyes S. 2003. Effects of a SARS‐associated coronavirus vaccine in monkeys. Lancet 362: 1895–1896.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>362</number></detail><extent unit="pages"><start>1895</start><end>1896</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>362</number></detail><extent unit="pages"><start>1895</start><end>1896</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA</title></titleInfo><name type="personal"><namePart type="given">LR</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Chiu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SH</namePart><namePart type="family">Yeh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WH</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PR</namePart><namePart type="family">Hsueh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WZ</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JY</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IJ</namePart><namePart type="family">Su</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SC</namePart><namePart type="family">Chang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Huang LR, Chiu CM, Yeh SH, Huang WH, Hsueh PR, Yang WZ, Yang JY, Su IJ, Chang SC, Chen PJ. 2004. Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. J Med Virol 73: 338–346.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>338</start><end>346</end></extent></part><relatedItem type="host"><titleInfo><title>J Med Virol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>338</start><end>346</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Kuiken</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Fouchier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Schutten</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GF</namePart><namePart type="family">Rimmelzwaan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">van Amerongen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">van Riel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JD</namePart><namePart type="family">Laman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">de Jong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">van Doornum</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Lim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AE</namePart><namePart type="family">Ling</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PK</namePart><namePart type="family">Chan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Tam</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MC</namePart><namePart type="family">Zambon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Gopal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">van der Werf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Escriou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Manuguerra</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Stohr</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Peiris</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AD</namePart><namePart type="family">Osterhaus</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, Laman JD, de Jong T, van Doornum G, Lim W, Ling AE, Chan PK, Tam JS, Zambon MC, Gopal R, Drosten C, van der Werf S, Escriou N, Manuguerra JC, Stohr K, Peiris JS, Osterhaus AD. 2003. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362: 263–270.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>362</number></detail><extent unit="pages"><start>263</start><end>270</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>362</number></detail><extent unit="pages"><start>263</start><end>270</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Profile of specific antibodies to the SARS‐associated coronavirus</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Xu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Li G, Chen X, Xu A. 2003. Profile of specific antibodies to the SARS‐associated coronavirus. N Engl J Med 349: 508–509.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>349</number></detail><extent unit="pages"><start>508</start><end>509</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>349</number></detail><extent unit="pages"><start>508</start><end>509</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS) associated corona virus in probable SARS patients</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Shi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Yi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q</namePart><namePart type="family">Ma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Cao</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liu Y, Shi Y, Li P, Li L, Yi Y, Ma Q, Cao C. 2004. Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS) associated corona virus in probable SARS patients. Clin Diag Lab Immunol 11: 227–228.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>227</start><end>228</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Diag Lab Immunol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>227</start><end>228</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Caution urged on SARS vaccines</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Marshall</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Enserink</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marshall E, Enserink M. 2004. Caution urged on SARS vaccines. Science 303: 944–946.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>303</number></detail><extent unit="pages"><start>944</start><end>946</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>303</number></detail><extent unit="pages"><start>944</start><end>946</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Clinical diagnostic criteria for severe acute respiratory syndrome (SARS) (on trial)</title></titleInfo><genre>other</genre><part><date>2003</date></part></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>A simple method of estimating fifty percent endpoints</title></titleInfo><name type="personal"><namePart type="given">LJ</namePart><namePart type="family">Reed</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Muench</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493–497.</note><part><date>1938</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>493</start><end>497</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Hyg</title></titleInfo><part><date>1938</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>493</start><end>497</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen‐capturing enzyme‐linked immunosorbent assay</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Shi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Yi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Kuang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Dong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q</namePart><namePart type="family">Ma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Cao</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shi Y, Yi Y, Li P, Kuang T, Li L, Dong M, Ma Q, Cao C. 2003. Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen‐capturing enzyme‐linked immunosorbent assay. J Clin Microbiol 41: 5781–5782.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>5781</start><end>5782</end></extent></part><relatedItem type="host"><titleInfo><title>J Clin Microbiol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>5781</start><end>5782</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Subbarao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">McAuliffe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Vogel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Fahle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Fischer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Tatti</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Packard</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Shieh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Zaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Murphy</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh W, Zaki S, Murphy B. 2004. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78: 3572–3577.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>3572</start><end>3577</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>3572</start><end>3577</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Detection of the anti‐SARS‐coronavirus antibody levels in 156 SARS Patients</title></titleInfo><name type="personal"><namePart type="given">HB</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JH</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XL</namePart><namePart type="family">Ouyang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Yu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SX</namePart><namePart type="family">Ma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XY</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LC</namePart><namePart type="family">Lu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YP</namePart><namePart type="family">Tian</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HY</namePart><namePart type="family">Liy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HM</namePart><namePart type="family">Xu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Yao</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wang HB, Liu JH, Ouyang XL, Yu Y, Ma SX, Li XY, Lu LC, Tian YP, Liy HY, Xu HM, Yao W. 2003. Detection of the anti‐SARS‐coronavirus antibody levels in 156 SARS Patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11: 441–443.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>441</start><end>443</end></extent></part><relatedItem type="host"><titleInfo><title>Zhongguo Shi Yan Xue Ye Xue Za Zhi</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>441</start><end>443</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>SARS under control, lab‐safety questions remain</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Watts</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Watts J. 2004. SARS under control, lab‐safety questions remain. Lancet 363: 1780.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>363</number></detail><extent unit="pages"><start>1780</start></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>363</number></detail><extent unit="pages"><start>1780</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Serological and molecular biologic methods for SARS‐associated coronavirus infection</title></titleInfo><name type="personal"><namePart type="given">HS</namePart><namePart type="family">Wu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SC</namePart><namePart type="family">Chiu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TC</namePart><namePart type="family">Tseng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SF</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JH</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YF</namePart><namePart type="family">Hsu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MC</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TL</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WZ</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TL</namePart><namePart type="family">Ferng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KH</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LC</namePart><namePart type="family">Hsu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LL</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JY</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HY</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SP</namePart><namePart type="family">Su</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SY</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TH</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IJ</namePart><namePart type="family">Su</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wu HS, Chiu SC, Tseng TC, Lin SF, Lin JH, Hsu YF, Wang MC, Lin TL, Yang WZ, Ferng TL, Huang KH, Hsu LC, Lee LL, Yang JY, Chen HY, Su SP, Yang SY, Lin TH, Su IJ. 2004. Serological and molecular biologic methods for SARS‐associated coronavirus infection. Taiwan Emerg Infect Dis 10: 304–310.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>304</start><end>310</end></extent></part><relatedItem type="host"><titleInfo><title>Taiwan Emerg Infect Dis</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>304</start><end>310</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice</title></titleInfo><name type="personal"><namePart type="given">ZY</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WP</namePart><namePart type="family">Kong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Roberts</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BR</namePart><namePart type="family">Murphy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Subbarao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GJ</namePart><namePart type="family">Nabel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. 2004. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428: 561–564.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>428</number></detail><extent unit="pages"><start>561</start><end>564</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>428</number></detail><extent unit="pages"><start>561</start><end>564</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Preparation and characterization of SARS in‐house reference antiserum</title></titleInfo><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YX</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LX</namePart><namePart type="family">Hu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q</namePart><namePart type="family">Gao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZS</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XM</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JT</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XJ</namePart><namePart type="family">Gong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LF</namePart><namePart type="family">Song</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YF</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SF</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JF</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Ning</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Gao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Qin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XP</namePart><namePart type="family">Dong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JG</namePart><namePart type="family">Wei</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GM</namePart><namePart type="family">Dong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WD</namePart><namePart type="family">Yin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhang JS, Liu YX, Hu LX, Gao Q, Zhang ZS, Zhang XM, Chen JT, Gong XJ, Song LF, Liu YF, Li J, Li SF, Huang JF, Ning Y, Gao H, Qin C, Dong XP, Wei JG, Dong GM, Yin WD. 2005. Preparation and characterization of SARS in‐house reference antiserum. Vaccine (in press).</note><part><date>2005</date></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2005</date></part></relatedItem></relatedItem><identifier type="istex">F066BD559402A5F38564C58EA794B07017CF14D3</identifier><identifier type="ark">ark:/67375/WNG-CTTG3L81-5</identifier><identifier type="DOI">10.1002/jmv.20431</identifier><identifier type="ArticleID">JMV20431</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-15</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-CTTG3L81-5/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000414 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000414 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F066BD559402A5F38564C58EA794B07017CF14D3
|texte= A serological survey on neutralizing antibody titer of SARS convalescent sera
}}
| This area was generated with Dilib version V0.6.33. |  |